Clinical trial registry record

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 10, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06765980
Last registry update
August 10, 2026
Status
Recruiting
Phase
Phase 1, Phase 2
Sponsor
Kriya Therapeutics, Inc.
Enrollment
62
Countries
United States, Canada, Israel, New Zealand
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
62
Population
ALL · 55 Years to 80 Years
Duration
2025-05-28 to 2027-12-15
Intervention
VV-14295
Comparator
Not reported
Outcomes measured
Incidence and severity of ocular and non-ocular adverse events, abnormal clinical laboratory values, abnormal physical…; Rate of GA progression as assessed by optical coherence tomography (OCT) — 12 months; Rate of GA progression as assessed by fundus autofluorescence (FAF) — 3, 6, and 12 months; Rate of GA progression as assessed by OCT — 3, 6, and 12 months; Visual function preservation as assessed by best-corrected visual acuity (BCVA) — 3, 6, and 12 months; Visual function preservation as assessed by low luminance visual acuity (LLVA) — 3, 6, and 12 months; Visual function preservation as assessed by microperimetry — 3, 6, and 12 months; VV-14295 transgene product expression — 12 months; Immune response to VV-14295 — 12 months; Vector shedding profile of VV-14295 — 12 months; Safety of Everads Injector — 1 day post-dose
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON